| Expression pattern: |
DN |
| Associated gene: |
Smad4, Smad2, Smad3, eIF4A3 |
| Associated microRNA: |
- |
| Biological function: |
Suppresses CRC progression/metastasis and inhibits TGF-beta-mediated migration and invasion; suppresses EMT. |
| Molecular mechanism: |
circPTEN1 directly binds Smad4 (MH2 domain) and disrupts Smad4 interaction with Smad2/3, reducing Smad complex formation and nuclear translocation, thereby suppressing transcription of EMT genes under TGF-beta1 stimulation; eIF4A3 binds flanking region to suppress circPTEN1 cyclization. |
| Biological pathway or process: |
TGF-beta/SMAD (inhibits); EMT (inhibits); metastasis (inhibits); migration (inhibits); invasion (inhibits) |
| Detected method: |
Q
B
H
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; RT-qPCR; Northern Blot; FISH / smFISH; ISH (In Situ Hybridization); Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; Transwell Assay; In Vivo Animal Model; Western Blot; Co-IP; IF (Immunofluorescence) |
| Clinical significance: |
Decreased circPTEN1 expression predicts poor survival; low circPTEN1 is associated with lymph node metastases, distant metastases, and advanced stage. |
| Description: |
circPTEN1 (hsa_circ_0002232) is down-regulated in colorectal/colon cancer and functions as a tumor suppressor. It directly binds Smad4 (MH2 domain) to block Smad2/3-Smad4 complex formation and nuclear translocation, thereby inhibiting TGF-beta/SMAD-driven EMT and metastasis. Low circPTEN1 expression is associated with advanced metastatic features and poorer overall survival. |
| Confidence score: |
0.8525 |